Wednesday, July 8, 2026
🇺🇸 FDA

pharma · SBRT · Covid19 · GRTX

Kailera Therapeutics

Galera Therapeutics

Kailera Therapeutics patent portfolio — 23 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
Status
Public
HQ
Waltham, Massachusetts, United States
Founded
2024
Employees
153
Programs
17
Drugs
7
Patents
23
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

Kailera Therapeutics patents

23 pharmaceutical patents indexed for Kailera Therapeutics. 0 expire within 24 months.

Kailera Therapeutics has 23 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

23 patents

Patent portfolio

  1. US 12220420

    Combination therapy for cancer treatment

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12077549

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11826373

    Methods for treatment of diseases

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11612608

    Methods of treating oral mucositis

    Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11246950

    Combination cancer immunotherapy with pentaaza macrocyclic ring complex

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11219614

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11066433

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10610533

    Methods of treating oral mucositis

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10597415

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10493081

    Methods for treatment of diseases

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10350193

    Super-oxide dismutase mimetics

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10137133

    Methods for treatment of diseases

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9855279

    Methods of treating oral mucositis

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9738669

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9738670

    Pentaaza macrocyclic ring complexes possessing oral bioavailability

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9642861

    Methods of treating oral mucositis

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9353069

    Super-oxide dismutase mimetics

    Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9198893

    Combination antitumor therapy

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9150837

    Polyethylene glycolated superoxide dismutase mimetics

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9149483

    Methods for treatment of diseases

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8486928

    Super-oxide dismutase mimetics

    Expires Mon Jul 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8217166

    Polyethylene glycolated superoxide dismutase mimetics

    Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Kailera Therapeutics have?

23 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Kailera Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.